## New Threats: Perspectives from the US and Israel BIOTERRORISM

## OPENING REMARKS

## Richard <mark>Zahn</mark> EDITORIAL

President Schering Laboratories

Statement for R. Zahn on Bioterrorism

Schering-Plough is proud to have been a supporter of the April 2002 International Conference on Bioterrorism. Since the attacks on America on September 11, 2001, leaders in every part of the health care industry have focused on the readiness of this country to respond to terrorism.

The first test came in the hours and days following the attacks on the World Trade Center and Pentagon, when health care professionals responded with dedication and professionalism.

The second test came, literally, in the mail. En velopes sent to the Hart Se-

nate Office Building and other locations delive red a new and chilling word to the country's vocabulary bioterrorism.

I am proud to say that the pharmaceutical industry is working in partnership with the gove rument to add ress the nation's health care priorities in light of the new reality of bioterrorism. In doing so, we are building on a legacy of partnership that began during World War II. The pharmaceutical industry distinguished itself then by mobilizing to meet the demand for penicillin. Today, on other fronts, we are making great strides in the wars against cancer, HIV-AIDS, and other serious diseases.

Whether it's with new research, in-



creased production or other expertise, the pharmaceutical industry is fully committed to helping America meet its current public health challenges and prepare for the future.

At Schering-Plough, we believe that the strength of America's response to the threat of bioterrorism is as vital to our national security as our militaryreadiness. All of us who are part of the health care system – doctors, hospitals, insurers, pharmaceutical companies and government – must work together as partners to keep our countrystrong and our citizens safe."

Richard Zahn

President Schering Laboratories

35